Nisa Leung is Managing Partner of Qiming Venture Partners, leading its health care investments. Qiming Venture Partners is a leading investment firm with over 530 portfolio companies.
She sits on the board of Zai Lab (NASDAQ:ZLAB; HKSE:9688), Caidya, Chain Medical Labs, Belief BioMed, Alamar Biosciences, Horizone, Vision Pro, SinoUnited Health among others. Her other investments include Gan & Lee (SSE:603087), New Horizon Health (HKSE:6606), SinoCellTech (SSE:688520), Sino Biological (SZSE:301047), Apollomics (NASDAQ:APLM), Schrödinger (NASDAQ:SDGR) , Structure Therapeutics (NASDAQ:GPCR), Berry Genomics (SZSE:000710), CITIC Pharma (acquired by Shanghai Pharmaceutical HKSE: 2607), Crown Bioscience (acquired by JSR Life Sciences), Aeonmed, NOVAST, Nurotron, Origene Technologies (acquired by VCAN Bio SSE:600645), MEDx, Goodwill (SSE:688246), Insilico Medicine, Jacobio (HKSE:1167), Hope Medicine, Sinotau, PlusLife, Zencore Biologics, Cognitact, Silicon Gene, Thorough Future among others.
Prior to joining Qiming, she was co-founder of Biomedic Holdings with operations and investments in medical devices, pharmaceuticals and health care services in China including Novamed Pharmaceuticals (acquired by SciClone NASDAQ:SCLN) and U-Systems (acquired by GE Healthcare). Nisa was Venture Partner of PacRim Ventures in Menlo Park, and was previously with Softbank/Mobius Venture Capital.
Nisa has been recognized by the Forbes Midas List for six consecutive years since 2019 and ranked top 2 in Best Women VCs List by Forbes China for three successive years since 2021 and among Most Powerful Women in Business by Fortune China in 2022 and 2023.
Nisa earned her MBA from Stanford Graduate School of Business and a BS from Cornell University. She is visiting lecturer at Harvard Law School, member of Stanford Graduate School of Business Advisory Council, trustee of the Hotchkiss School and serves as an Independent Non-executive Director of the Hong Kong Exchanges and Clearing Limited (“HKEX”).
